Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other financing activities (2020 - 2024)

Ultragenyx Pharmaceutical has reported Other financing activities over the past 5 years, most recently at $7.0 million for Q3 2024.

  • Quarterly Other financing activities changed N/A to $7.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $7.0 million for FY2024, N/A changed from the prior year.
  • Other financing activities was $7.0 million for Q3 2024 at Ultragenyx Pharmaceutical, up from $28000.0 in the prior quarter.
  • Over five years, Other financing activities peaked at $7.0 million in Q3 2024 and troughed at -$147000.0 in Q3 2022.
  • The 5-year median for Other financing activities is -$72500.0 (2020), against an average of $392000.0.
  • Year-over-year, Other financing activities plummeted 239.39% in 2021 and then soared 407.04% in 2022.
  • A 5-year view of Other financing activities shows it stood at -$87000.0 in 2020, then tumbled by 63.22% to -$142000.0 in 2021, then soared by 407.04% to $436000.0 in 2022, then tumbled by 93.58% to $28000.0 in 2023, then surged by 24900.0% to $7.0 million in 2024.
  • Per Business Quant, the three most recent readings for RARE's Other financing activities are $7.0 million (Q3 2024), $28000.0 (Q4 2023), and -$56000.0 (Q2 2023).